Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 20, 2007

Santarus Receives $5M Milestone Fee from Schering-Plough

  • Santarus achieved a $5-million milestone in its license agreement with Schering-Plough HealthCare Products for its proton pump inhibitor (PPI).

    The over-the-counter (OTC) license agreement gives Schering-Plough the right to develop, manufacture, and commercialize OTC products using Santarus' PPI technology with the lower-dosage strength of 20 mg of omeprazole for heartburn-related indications in the U.S. and Canada. Santarus will continue to manufacture and sell its Zegerid prescription products in both 20-mg and 40-mg dosage strengths in the U.S.

    In addition to the $15 million Santarus received upfront and this milestone fee, the company could receive up to $60 million in milestone payments plus low double-digit royalties. In turn, Santarus will be obligated to pay royalties to the University of Missouri on net sales of any such OTC products.

  • You’re all set! Thank you for subscribing to GEN Highlights.